Todays Report: Today, Insider Selling: Hologic Inc. (HOLX) VP Sold $115,841.36 in Stock

Today, Insider Selling: Hologic Inc. (HOLX) VP Sold $115,841.36 in Stock

Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 3,023 shares of Hologic stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $38.32, for a total transaction of $115,841.36. Following the completion of the sale, the vice president now owns 13,260 shares of the company’s stock, valued at $508,123.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Karleen Marie Oberton also recently made the following trade(s): On Tuesday, November 15th, Karleen Marie Oberton sold 1,211 shares of Hologic stock. The shares were sold at an average price of $36.55, for a total transaction of $44,262.05. On Tuesday, November 8th, Karleen Marie Oberton sold 984 shares of Hologic stock. The shares were sold at an average price of $38.57, for a total transaction of $37,952.88. On Monday, November 7th, Karleen Marie Oberton sold 522 shares of Hologic stock. The shares were sold at an average price of $38.53, for a total transaction of $20,112.66. On Monday, October 10th, Karleen Marie Oberton sold 31,470 shares of Hologic stock. The shares were sold at an average price of $40.00, for a total transaction of $1,258,800.00.

Shares of Hologic Inc. (NASDAQ:HOLX) opened at 38.97 on Friday. Hologic Inc. has a 12 month low of $31.84 and a 12 month high of $41.66. The firm’s 50-day moving average is $37.93 and its 200-day moving average is $36.78. The company has a market cap of $10.84 billion, a PE ratio of 33.59 and a beta of 1.13.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.02. Hologic had a net margin of 11.68% and a return on equity of 26.76%. The firm earned $726.80 million during the quarter, compared to the consensus estimate of $721.52 million. During the same period last year, the firm earned $0.43 EPS. The business’s quarterly revenue was up 3.4% compared to the same quarter last year. On average, equities research analysts predict that Hologic Inc. will post $2.15 earnings per share for the current year.

Several research analysts have commented on HOLX shares. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, November 7th. Evercore ISI restated a “buy” rating and set a $43.00 price objective on shares of Hologic in a research report on Saturday, October 15th. Leerink Swann restated a “buy” rating and set a $46.00 price objective on shares of Hologic in a research report on Thursday, July 28th. Canaccord Genuity set a $45.00 price objective on shares of Hologic and gave the company a “buy” rating in a research report on Thursday, July 28th. Finally, Jefferies Group boosted their price objective on shares of Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $43.20.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Oakbrook Investments LLC bought a new stake in Hologic during the second quarter valued at $907,000. Adage Capital Partners GP L.L.C. bought a new stake in Hologic during the first quarter valued at $12,620,000. Stoneridge Investment Partners LLC bought a new stake in Hologic during the second quarter valued at $1,868,000. Seven Eight Capital LLC boosted its stake in Hologic by 445.7% in the first quarter. Seven Eight Capital LLC now owns 25,589 shares of the company’s stock valued at $883,000 after buying an additional 20,900 shares during the period. Finally, Capstone Asset Management Co. boosted its stake in Hologic by 65.9% in the second quarter. Capstone Asset Management Co. now owns 44,092 shares of the company’s stock valued at $1,526,000 after buying an additional 17,516 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Hologic

Related posts

Leave a Comment